✦ LIBER ✦

Hemodynamic Effects of the Angiotensin II Receptor Antagonist Irbesartan in Patients With Cirrhosis and Portal Hypertension

✍ Scribed by Michael Schepke; Eva Werner; Erwin Biecker; Peter Schiedermaier; Jörg Heller; Markus Neef; Birgit Stoffel-Wagner; Ulrich Hofer; Wolfgang H. Caselmann; Tilman Sauerbruch

Book ID: 119756310
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 210 KB
Volume: 121
Category: Article
ISSN: 0016-5085
DOI: 10.1053/gast.2001.26295

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of Irbesartan, a Receptor Selec

Efficacy of Irbesartan, a Receptor Selective Antagonist of Angiotensin II, in Reducing Portal Hypertension

✍ Wilma Debernardi-Venon; Claudio Barletti; Carlo Alessandria; Alfredo Marzano; M. 📂 Article 📅 2002 🏛 Springer US 🌐 English ⚖ 192 KB

Hemodynamic effects of octreotide in pat

Hemodynamic effects of octreotide in patients with cirrhosis and portal hypertension

✍ RUIZDELARBOL, L 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Hemodynamic and biochemical effects of A

Hemodynamic and biochemical effects of AT1-receptor antagonist irbesartan in essential hypertension

✍ AH van den Meiracker; PJJ Admiraal; J Sissmann; AJ Man in 'tVeld; FHM Derkx; MAD 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 184 KB

Efficacy and Tolerability of Irbesartan,

Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension

✍ Dr Robert M. Guthrie, Ravi Saini, Theodore Herman, Warren Pleskow, Dennis Sprech 📂 Article 📅 1998 🏛 Springer International Publishing AG 🌐 English ⚖ 283 KB

Effect of losartan, an Angiotensin II re

Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis

✍ Arved Winfried Schneider; Johann Friedrich Kalk; Christian Peter Klein 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

Administration of angiotensin II causes an increase in portal pressure, and plasma concentration of angiotensin II is elevated in patients with cirrhosis, suggesting that angiotensin II may be involved in the pathogenesis of portal hypertension in cirrhosis. We evaluated the effect of the orally act

Haemodynamic effects of chronic administ

Haemodynamic effects of chronic administration of losartan, an angiotensin II receptor anatagonist, in patients with cirrhosis and portal hypertension

✍ D. Tripathi; G. Therapondos; H.F. Lui; D.J. Webb; P.C. Hayes 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 112 KB